Halozyme Therapeutics Raises 2025, 2026 Outlooks

MT Newswires Live01-28

Halozyme Therapeutics (HALO) said Wednesday it now expects 2025 preliminary total revenue in the range of $1.39 billion to $1.40 billion, up from its prior range of $1.30 billion to $1.38 billion.

Analysts polled by FactSet expect $1.34 billion.

The biopharmaceutical company said it now expects 2026 non-GAAP earnings in the range of $7.75 to $8.25 per diluted share, up from its previous range of $6.50 to $7. Analysts polled by FactSet expect $8.22.

Total revenue for the year is now expected in the range of $1.71 billion to $1.81 billion, up from its prior outlook of $1.43 billion to $1.53 billion. Analysts surveyed by FactSet expect $1.69 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606715178?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606715178","market":"fut","top_or_hot":-1,"title":"Halozyme Therapeutics Raises 2025, 2026 Outlooks","media":"MT Newswires Live","content":"<html><body><p> Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HALO) said Wednesday it now expects 2025 preliminary total revenue in the range of $1.39 billion to $1.40 billion, up from its prior range of $1.30 billion to $1.38 billion.</p><p>Analysts polled by FactSet expect $1.34 billion.</p><p>The biopharmaceutical company said it now expects 2026 non-GAAP earnings in the range of $7.75 to $8.25 per diluted share, up from its previous range of $6.50 to $7. Analysts polled by FactSet expect $8.22.</p><p>Total revenue for the year is now expected in the range of $1.71 billion to $1.81 billion, up from its prior outlook of $1.43 billion to $1.53 billion. Analysts surveyed by FactSet expect $1.69 billion.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme Therapeutics Raises 2025, 2026 Outlooks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme Therapeutics Raises 2025, 2026 Outlooks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-28 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HALO) said Wednesday it now expects 2025 preliminary total revenue in the range of $1.39 billion to $1.40 billion, up from its prior range of $1.30 billion to $1.38 billion.</p><p>Analysts polled by FactSet expect $1.34 billion.</p><p>The biopharmaceutical company said it now expects 2026 non-GAAP earnings in the range of $7.75 to $8.25 per diluted share, up from its previous range of $6.50 to $7. Analysts polled by FactSet expect $8.22.</p><p>Total revenue for the year is now expected in the range of $1.71 billion to $1.81 billion, up from its prior outlook of $1.43 billion to $1.53 billion. Analysts surveyed by FactSet expect $1.69 billion.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2606715178","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606715178","pubTimestamp":1769602068,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Halozyme Therapeutics  said Wednesday it now expects 2025 preliminary total revenue in the range of $1.39 billion to $1.40 billion, up from its prior range of $1.30 billion to $1.38 billion.Analysts polled by FactSet expect $1.34 billion.The biopharmaceutical company said it now expects 2026 non-GAAP earnings in the range of $7.75 to $8.25 per diluted share, up from its previous range of $6.50 to $7. Analysts polled by FactSet expect $8.22.Total revenue for the year is now expected in the range of $1.71 billion to $1.81 billion, up from its prior outlook of $1.43 billion to $1.53 billion. Analysts surveyed by FactSet expect $1.69 billion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技"},"translate_title":"Halozyme Therapeutics上调2025年、2026年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1.5},"content_text":"Halozyme Therapeutics (HALO) said Wednesday it now expects 2025 preliminary total revenue in the range of $1.39 billion to $1.40 billion, up from its prior range of $1.30 billion to $1.38 billion.Analysts polled by FactSet expect $1.34 billion.The biopharmaceutical company said it now expects 2026 non-GAAP earnings in the range of $7.75 to $8.25 per diluted share, up from its previous range of $6.50 to $7. Analysts polled by FactSet expect $8.22.Total revenue for the year is now expected in the range of $1.71 billion to $1.81 billion, up from its prior outlook of $1.43 billion to $1.53 billion. Analysts surveyed by FactSet expect $1.69 billion.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606715178","isCrawlerRequest":true}